Primary Site >> Pancreatic Cancer
Gene >> IDO1
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
|
Ref: Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. PMID: 18471709 Ref: MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. PMID: 18713982 |
Ref: Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. PMID: 20124451 Ref: FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas. PMID: 21051918 |
Ref: Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. PMID: 21406395 |
Ref: Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2. PMID: 23122865 |
Ref: Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. PMID: 25274283 |
Ref: Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. PMID: 26134178 |
Ref: Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer. PMID: 28303855 Ref: Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer. PMID: 28470686 Ref: Carbidopa is an activator of aryl hydrocarbon receptor with potential for cancer therapy. PMID: 28963435 Ref: Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. PMID: 29180759 |
Ref: Companies Scaling Back IDO1 Inhibitor Trials. PMID: 29848606 Ref: Indoleamine 2, 3-dioxygenase and B7-H1 expressions as prognostic and follow-up markers in human pancreatic carcinoma. PMID: 30029936 |